CALDERWOOD & HARKNESS LLP PRIVILEGED AND CONFIDENTIAL ATTORNEY WORK PRODUCT
MEMORANDUM
Subject Matter: Regulatory requirements for qualified cost-sharing arrangements ("QCSAs"), platform contribution transaction ("PCT") payment methodologies, reasonably anticipated benefit ("RAB") shares, and documentary compliance requirements under Treas. Reg. § 1.482-7, as applied to the cost-sharing arrangement between PPC and Penterra Biopharma International DAC ("PBI").
Distribution: Restricted to engagement team and authorized PPC personnel (Marcus Whitfield, VP of Global Tax; Deborah Staines, General Counsel).
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to provide the engagement team with a comprehensive analysis of the regulatory framework governing qualified cost-sharing arrangements under Treas. Reg. § 1.482-7, in order to inform the defense of PPC's cost-sharing arrangement with PBI in the ongoing IRS Large Business and International ("LB&I") Division examination covering tax years 2017 through 2020 (Exam Team ID LB&I-NE-TP-2022-00641).
The cost-sharing arrangement ("CSA") between PPC and PBI, effective July 1, 2012, governs PBI's acquisition of rights to develop and exploit PPC's pharmaceutical intellectual property portfolio outside the Americas (defined as North America, Central America, South America, and the Caribbean), in exchange for a lump-sum platform contribution transaction ("PCT") payment of $312 million and ongoing cost-sharing payments based on PBI's reasonably anticipated benefits ("RAB") from exploiting the cost-shared intangibles. The CSA covers PPC's portfolio of oncology, immunology, and rare-disease therapeutics, including the company's most significant revenue-generating products: Veritaxol, Imvara, and Cerulon.
The IRS is examining tax years 2017 through 2020 and is expected to challenge both the PCT valuation and the annual cost-sharing ratios. Specifically, the IRS has indicated that it values the PCT at $852 million (compared to PPC's $312 million), and the IRS proposes increasing PBI's cost-sharing percentages by approximately eight to twelve percentage points for each examination year, from PBI's reported shares ranging from 38.2% to 42.7% to proposed shares ranging from 48.2% to 53.7%. The total proposed adjustment to cost-sharing payments across the four examination years is approximately $235.01 million. In addition, the IRS has proposed a substantial valuation misstatement penalty under IRC § 6662(e) of approximately $15.98 million.
This memorandum addresses the following core issues:
1. Eligibility requirements for QCSA status — whether PPC and PBI satisfy the requirements for controlled participants under Treas. Reg. § 1.482-7(j)(1), including the substantive involvement standard.
2. PCT payment requirements and valuation methodologies — whether PPC's $312 million PCT payment falls within the arm's-length range, with particular attention to the income method under § 1.482-7(g)(4) and the competing discount rate and revenue projection assumptions.
3. RAB share calculation standards — whether PBI's cost-sharing percentages (38.2% to 42.7%) are consistent with the reasonably anticipated benefits standard under § 1.482-7(e), and whether the IRS's proposed increases are supportable.
4. Cost pool composition and allocation — whether PPC's qualified R&D cost pools for the examination years are properly composed under § 1.482-7(d), including the treatment of stock-based compensation in light of the Altera litigation.
5. Documentation and administrative requirements — whether PPC's contemporaneous documentation satisfies the requirements of § 1.482-7(k) and provides a basis for penalty protection under IRC § 6662(e)(3)(B).
6. Consequences of noncompliance — the potential penalties and adjustments that could result from a finding that PPC's CSA fails to qualify as a QCSA or that PPC's cost-sharing ratios and PCT payment are not arm's-length.
Key Conclusion: Based on the analysis set forth below, PPC's CSA satisfies the structural and documentary requirements of Treas. Reg. § 1.482-7, and PPC's cost-sharing ratios and PCT payment are defensible under the regulatory framework. Both PPC and PBI are bona fide controlled participants with substantive involvement in the intangible development activity. PBI's RAB shares are based on reasonable, contemporaneous projections that are consistent with actual revenue data. The PCT payment of $312 million falls within the arm's-length range as determined by a discounted cash flow analysis applying an appropriate risk-adjusted discount rate. The IRS's proposed adjustments rely on a lower discount rate and more aggressive revenue projections that are subject to challenge, and the IRS's attempt to use an alleged PCT undervaluation to inflate the ongoing cost-sharing ratios lacks a clear regulatory basis. PPC's contemporaneous documentation, prepared by Crestfield & Associates LLP, satisfies the regulatory requirements and provides a strong foundation for penalty protection under IRC § 6662(e)(3)(B).
This memorandum should be read in conjunction with the companion memoranda on the IRC § 482 arm's-length standard analysis (dated July 20, 2022), the royalty rate analysis under Treas. Reg. § 1.482-4 (to be issued August 12, 2022), the economic substance doctrine and DEMPE analysis (forthcoming August 18, 2022), and the penalty protection analysis (forthcoming September 2, 2022).
II. Factual Background
A. The PPC Corporate Structure
Penterra Pharmaceuticals Corp. ("PPC") is a Delaware corporation, publicly traded on the Nasdaq Global Select Market under the ticker symbol "PPCA," with its principal executive offices located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceuticals and biotechnology company focused on the development, manufacturing, and commercialization of therapeutic products in three principal areas: oncology, immunology, and rare-disease therapeutics.
For its fiscal year ending December 31, 2020, PPC reported annual revenue of approximately $6.82 billion, pre-tax income of approximately $1.47 billion, and a global workforce of approximately 14,500 employees. PPC's U.S. operations include substantial research and development facilities in Princeton Junction, New Jersey; Cambridge, Massachusetts; and San Diego, California. The company's R&D operations are led by its Chief Scientific Officer, Dr. Miriam Hecht, and supported by approximately 4,200 research, clinical development, and regulatory affairs professionals in the United States.
PPC's key officers during the examination years include: Catherine Falk, Chief Executive Officer; Rajesh Iyer, Chief Financial Officer; Deborah Staines, General Counsel; and Marcus Whitfield, Vice President of Global Tax. Each of these individuals has been involved at various points in the structuring, implementation, and management of the cost-sharing arrangement that is the subject of this memorandum.
PPC owns 100% of the equity interests of Penterra Holdings Luxembourg S.à r.l. ("PHL"), a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg (Registre de Commerce et des Sociétés Number B 168452). PHL in turn owns 100% of the ordinary shares of PBI. Importantly, PHL is treated as a disregarded entity for U.S. federal income tax purposes pursuant to Treasury Regulation § 301.7701-3. Accordingly, for U.S. tax purposes, PPC is treated as the direct owner of PBI.
Penterra Biopharma International DAC ("PBI") is a Designated Activity Company organized under the laws of Ireland, with its registered office located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland (Irish Tax Reference Number 3218764T). PBI's Managing Director is Aidan Naughton, who has served in that capacity since PBI's incorporation. PBI functions as the intellectual property-holding company and principal for the non-Americas commercialization of PPC products. In this capacity, PBI manages contract manufacturing arrangements, distribution agreements, regulatory submissions, and commercial strategy across PPC's EMEA and APAC territories. PBI bears market risk for these non-Americas territories and exercises independent commercial decision-making authority, including pricing, market entry, and distribution partner selection across sixty-eight country markets.
For its fiscal year ending December 31, 2020, PBI reported revenue of approximately €2.14 billion, pre-tax income of approximately €1.06 billion, and a workforce of 185 employees. PBI's headcount has grown significantly from fifty-two employees at the time of its establishment in 2012, reflecting the expansion of its commercial and regulatory operations. PBI's employees include regulatory affairs professionals, medical affairs scientists, commercial strategy managers, supply chain and operations specialists, and finance and compliance personnel, all based in Dublin. PBI occupies approximately 18,000 square feet of office space at its Sandyford Business Park location.
PBI claims benefits under Ireland's Knowledge Development box ("KDB") regime, which provides an effective tax rate of 6.25% on qualifying income derived from qualifying intellectual property assets. PBI has applied the KDB rate to eligible income beginning with fiscal year 2016. PBI's remaining trading income is subject to Ireland's standard corporate tax rate of 12.5%.
Penterra Manufacturing Ireland Ltd. ("PMI") is an Irish private limited company (Companies Registration Office Number 512347) that operates as a contract manufacturer for PBI under a cost-plus arrangement. PMI is registered at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland, and employs approximately 620 personnel in pharmaceutical manufacturing operations. PMI manufactures active pharmaceutical ingredients and finished dosage forms for PBI's non-Americas distribution under an intercompany contract manufacturing agreement that provides for compensation at cost plus a markup of 8%, consistent with comparable uncontrolled transaction benchmarks for contract pharmaceutical manufacturing services. PMI is not a participant in the CSA and its operations are analyzed separately under the § 1.482-1 services framework.
PBI maintains its primary banking relationship with Glenmore Bank Ireland plc, which provides treasury management, foreign exchange, and credit facilities to PBI in support of its non-Americas commercial operations.
B. The Cost-Sharing Arrangement
PBI was incorporated on March 15, 2012. The CSA between PPC and PBI was executed on June 28, 2012, and became effective as of July 1, 2012. The CSA was negotiated, drafted, and reviewed by PPC's internal tax department under the direction of Marcus Whitfield, with transfer pricing advice provided by Crestfield & Associates LLP (engagement partner Martin Ogilvy; transfer pricing partner Susan Lam). Legal review of the CSA agreement was conducted by PPC's General Counsel, Deborah Staines, in consultation with outside counsel.
Under the terms of the CSA, PBI acquired the right to develop and exploit PPC's pharmaceutical intellectual property portfolio outside the Americas, defined in the CSA as including North America (the United States and Canada), Central America, South America, and the Caribbean (collectively, the "Americas"). The non-Americas territory, assigned to PBI under the CSA, encompasses all countries and territories in EMEA (Europe, the Middle East, and Africa) and APAC (Asia-Pacific), representing approximately sixty-eight distinct country markets as of the examination years.
In exchange for the acquisition of rights to PPC's pre-existing IP portfolio and the right to participate in the ongoing intangible development activity, PBI agreed to two forms of consideration:
(a) A lump-sum PCT payment of $312 million, payable to PPC on July 1, 2012, representing the arm's-length buy-in to pre-existing intellectual property, primarily consisting of clinical-stage and approved oncology compounds, associated know-how, and related regulatory filings. The PCT payment was made in cash on the effective date of the CSA.
(b) Ongoing cost-sharing payments proportional to PBI's reasonably anticipated benefits from the intangible development activity, calculated annually based on PBI's projected share of total benefits from the cost-shared intangibles as described more fully in Section V below.
The key pharmaceutical products covered by the CSA during the examination years include:
• Veritaxol (oncology): 2020 global net sales of approximately $3.12 billion, of which non-Americas net sales were approximately $1.34 billion (approximately 43% of global net sales). Veritaxol is PPC's largest revenue-generating product and a cornerstone of the CSA cost-sharing analysis.
• Imvara (immunology): 2020 global net sales of approximately $1.87 billion, of which non-Americas net sales were approximately $0.79 billion (approximately 42% of global net sales). Imvara received its first European marketing authorization in 2014 and has experienced strong growth in the EMEA region.
• Cerulon (rare disease): 2020 global net sales of approximately $0.62 billion, of which non-Americas net sales were approximately $0.28 billion (approximately 45% of global net sales). Cerulon addresses a rare metabolic disorder with limited treatment options and has achieved orphan drug designations in multiple jurisdictions.
PBI's cost-sharing ratios for the examination years, reflecting PBI's share of the total qualified R&D costs incurred in the intangible development activity, were as follows:
The gradual increase in PBI's cost-sharing percentage from 38.2% in 2017 to 42.7% in 2020 reflects the growth of non-Americas revenue as a proportion of global revenue, driven by PBI's expansion into additional APAC markets, increasing market penetration in established European markets, and new regulatory approvals obtained by PBI in non-Americas jurisdictions.
Separately from the CSA, PBI licensed certain legacy pharmaceutical compounds (pre-2012 vintage, not covered by the scope of the CSA) from PPC under a separate intercompany licensing agreement at a royalty rate of 4.5% of net sales. This legacy licensing arrangement is governed by Treas. Reg. § 1.482-4 and is analyzed in the companion memorandum on royalty rate analysis to be issued on August 12, 2022. The legacy license and the CSA are distinct agreements covering different intellectual property, and they should be analyzed separately under the arm's-length standard.
C. PBI's Functions and Substance
The functional profile of PBI is a critical element of the defense of the CSA, particularly in light of the anticipated IRS challenge that PBI lacks sufficient substance to qualify as a bona fide controlled participant. The following facts establish PBI's substantive involvement in the intangible development activity and its independent commercial operations.
Personnel and Operations. As of December 31, 2020, PBI employed 185 individuals in Dublin, Ireland, representing a significant increase from the 52 employees present at the time of PBI's establishment in 2012. PBI's workforce includes professionals in regulatory affairs, medical affairs, commercial strategy, market access, supply chain management, legal and compliance, and finance and accounting. PBI occupies approximately 18,000 square feet of dedicated office space at Sandyford Business Park in Dublin, with plans for expansion to approximately 25,000 square feet in 2022.
Commercial Decision-Making. PBI bore market risk for the non-Americas territories and made key commercial decisions independently, including product pricing for each of the sixty-eight country markets, market entry strategy and sequencing, distribution partner selection and management, reimbursement and market access negotiations with governmental health authorities and private payors, and promotional strategy development. These decisions were made by PBI's Dublin-based management team under the direction of Managing Director Aidan Naughton, and were subject to oversight by PBI's board of directors.
Board Governance. PBI's board of directors held forty-two meetings in Dublin during the 2017–2020 examination period, consisting of sixteen regular quarterly meetings and twenty-six special sessions convened to address specific commercial, regulatory, and strategic matters. Board meeting minutes, which have been produced to the engagement team, document substantive deliberations on pricing decisions, market entry strategies, manufacturing arrangements, and regulatory submissions. The board's composition included both PPC-designated directors and independent Irish-resident directors, consistent with Irish corporate governance requirements.
Regulatory Expenditures. PBI incurred cumulative regulatory expenditures and submission costs of approximately €47.2 million during the 2017–2020 period. These expenditures included costs related to European Medicines Agency ("EMA") marketing authorization applications, national regulatory submissions in APAC markets, post-marketing surveillance and pharmacovigilance activities, and ongoing compliance with national and regional regulatory requirements. PBI maintained a dedicated regulatory affairs team in Dublin that managed these activities and coordinated with PPC's U.S.-based regulatory affairs group as necessary.
Capital Expenditures and Investment. In addition to its regulatory expenditures, PBI invested in information technology systems, office infrastructure, and commercial analytics capabilities during the examination period. PBI also maintained its contract manufacturing arrangement with PMI, overseeing the manufacturing and supply chain for its non-Americas territories.
The totality of these facts supports the conclusion that PBI is a substantive operating entity with genuine commercial functions, not merely a passive IP-holding vehicle. PBI's growing headcount, independent decision-making authority, significant regulatory investments, and Dublin-based board governance all demonstrate that PBI satisfies the substantive involvement requirements for a controlled participant under Treas. Reg. § 1.482-7(j)(1).
D. The IRS Examination
The IRS opened an examination of PPC's federal income tax returns for tax years 2017 through 2020 on May 16, 2022, as evidenced by a Letter 2205-A (Information Document Request). The examination is being conducted by the LB&I Division, Northeast Region, Transfer Pricing Practice Area, under Exam Team ID LB&I-NE-TP-2022-00641.
The IRS examination team is composed of the following personnel:
• Gerald Meskill, Supervisory Revenue Agent (Team Manager)
• Patricia Dunleavy, Lead Revenue Agent
• Dr. Alan Washburne, IRS Economist
• Franklin Rosario, Attorney-Advisor (IRS Office of Chief Counsel)
• Donna Hirabayashi, Senior Counsel
Calderwood & Harkness LLP was engaged by PPC on June 2, 2022, to represent PPC in the examination. Forms 2848 (Power of Attorney and Declaration of Representative) were filed on June 8, 2022, covering Leonard Cross (Responsible Partner), Sylvia Hartwell (Billing Partner), Garrett Simmons (Lead Associate), and Leila Nazari (Working Associate). All four attorneys have been designated as authorized representatives for the examination.
The Whitmore Valuation Group LLC was retained as a testifying expert and consulting economist under a Kovel arrangement, pursuant to a Kovel letter executed on June 20, 2022 (reference 1018-00009-KV). Under the Kovel arrangement, the Whitmore Valuation Group's work product and communications with Calderwood & Harkness are protected by the attorney-client privilege and work-product doctrine, provided that such work is conducted at the direction of counsel and in anticipation of litigation. The Whitmore engagement is led by Dr. Helena Vasquez (lead economist) and supported by Dr. Rohan Chakrabarti (supporting economist). Dr. Vasquez has extensive experience in pharmaceutical transfer pricing disputes and has testified as an expert witness in multiple Tax Court proceedings involving cost-sharing arrangements.
PPC's original transfer pricing documentation for tax years 2017 through 2020 was prepared by Crestfield & Associates LLP under the direction of engagement partner Martin Ogilvy and transfer pricing partner Susan Lam. The documentation was prepared contemporaneously with the filing of PPC's federal income tax returns for each examination year and covers the CSA methodology, cost pool composition, RAB share calculations, and PCT valuation support. PPC was not enrolled in the Compliance Assurance Process ("CAP") for any of the examination years, and thus the examination is proceeding through the standard LB&I examination process.
Based on preliminary communications with the IRS examination team and the initial Information Document Requests, we anticipate that the IRS will advance three principal challenges:
1. PCT Undervaluation. The IRS has indicated, through its economist Dr. Washburne, that it has independently valued the PCT at approximately $852 million, compared to PPC's $312 million. The IRS's valuation applies the income method with a lower weighted average cost of capital ("WACC") of 7.2% (compared to PPC's 9.8%) and higher revenue growth projections for PBI's non-Americas territories. Although the PCT payment was made in 2012 and that year is outside the scope of the current examination, the IRS intends to use the alleged PCT undervaluation as a basis for adjusting the ongoing cost-sharing ratios and royalty rates for tax years 2017 through 2020, effectively seeking to capture the residual value of the allegedly underpaid PCT through increased annual payments.
2. CSA Cost-Sharing Ratio Adjustments. The IRS proposes increasing PBI's cost-sharing percentage by eight to twelve percentage points for each examination year, asserting that PPC's projections of reasonably anticipated benefits understated the non-Americas share of benefits. The proposed adjustments would increase PBI's cost-sharing payments by a total of approximately $235.01 million over the four examination years.
3. Economic Substance Challenge. The IRS may assert that key DEMPE functions (Development, Enhancement, Maintenance, Protection, and Exploitation of intangibles) remained in the United States and were performed by PPC personnel, and that PBI lacked sufficient economic substance to justify its claimed share of intangible-related income. This challenge, if successful, could support a recharacterization of the CSA or an assertion that PBI's contributions to the IDA were not sufficient to justify its status as a controlled participant.
The delta between PPC's and the IRS's positions on the PCT is $540 million ($852 million minus $312 million). The total proposed CSA adjustments for the examination years, net of a $42.65 million correlative offset that the IRS has allowed, are approximately $192.36 million. In addition, the IRS has proposed a substantial valuation misstatement penalty under IRC § 6662(e) of approximately $15.98 million, calculated as 20% of the underpayment attributable to the proposed adjustments.
III. Regulatory Framework — Treas. Reg. § 1.482-7
A. Overview and Purpose of the QCSA Regulations
Treasury Regulation § 1.482-7 provides the governing regulatory framework for qualified cost-sharing arrangements between controlled participants. Understanding the history, purpose, and structure of these regulations is essential to evaluating the defensibility of PPC's CSA with PBI.
Historical Development. The cost-sharing regulations have evolved significantly over the past several decades. The original cost-sharing regulations, adopted in 1995, provided a relatively streamlined framework for controlled parties to share the costs of developing intangible property in proportion to their anticipated benefits. However, the IRS and Treasury Department concluded that these regulations were insufficient to address the increasingly complex cost-sharing structures employed by multinational enterprises, particularly in the technology and pharmaceutical sectors.
In 2009, the IRS issued temporary regulations under § 1.482-7T, which introduced substantially more detailed rules governing cost-sharing arrangements. These temporary regulations introduced the concept of "platform contribution transactions" ("PCTs"), requiring arm's-length compensation for pre-existing resources, capabilities, or rights contributed by one participant to the CSA that had been developed outside the intangible development activity. The temporary regulations also introduced new PCT valuation methods, including the income method, the acquisition price method, and the market capitalization method.
The temporary regulations were finalized in 2011, with certain modifications, as Treas. Reg. § 1.482-7. The final regulations retained the core structure of the temporary regulations, including the PCT requirements and specified valuation methods, and made refinements to the cost pool composition rules, the reasonably anticipated benefits standards, and the documentation and administrative requirements. The PPC/PBI CSA, which became effective on July 1, 2012, is governed by these final 2011 regulations.
Relationship to IRC § 482. Section 482 of the Internal Revenue Code grants the Secretary of the Treasury broad authority to "distribute, apportion, or allocate gross income, deductions, credits, or allowances" between two or more organizations, trades, or businesses owned or controlled by the same interests, if the Secretary determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses. The QCSA regulations under § 1.482-7 are a specific application of the arm's-length standard that governs all § 482 determinations. The best method rule of § 1.482-1(d) — which requires the selection of the transfer pricing method that provides the most reliable measure of an arm's-length result under the facts and circumstances — applies to all determinations under § 1.482-7, including both the PCT valuation and the cost-sharing ratio calculations.
Nature of a QCSA. A QCSA is not a distinct legal form or entity. Rather, it is a contractual arrangement between two or more controlled participants to share the costs and risks of developing intangible property in proportion to their reasonably anticipated benefits from exploiting that property. The qualifying cost-sharing arrangement must satisfy the administrative, substantive, and documentation requirements of § 1.482-7 in order to be respected as a QCSA. If an arrangement fails to meet these requirements, the IRS may disregard the arrangement in whole or in part and apply the general § 482 rules (including § 1.482-4 for intangible property and § 1.482-9 for services) to reallocate income among the controlled participants.
Distinction Between Pre-2009 and Post-2009 Regulatory Regimes. The pre-2009 cost-sharing regulations did not include the detailed PCT framework introduced by the 2009 temporary regulations. Under the earlier regime, buy-in payments were required when a participant contributed pre-existing intangibles to the arrangement, but the valuation methodology was less prescriptive. The post-2009 framework (as finalized in 2011) introduced specified PCT valuation methods, more detailed cost pool composition rules, and enhanced documentation and administrative requirements. Because the PPC/PBI CSA was executed in 2012, it is subject to the post-2009 regulatory framework in all respects.
B. Eligibility Requirements for Controlled Participants
Treasury Regulation § 1.482-7(j)(1) defines a "controlled participant" as a member of a controlled group that is reasonably anticipated to benefit from the intangible development activity. Each controlled participant must satisfy several requirements to be recognized as a bona fide participant in the QCSA.
Definition and Requirements. Under the regulations, each controlled participant must:
1. Commit to bear a share of IDA costs. Each participant must commit to, and actually bear, its share of the costs of the intangible development activity in proportion to its reasonably anticipated benefits from exploiting the cost-shared intangibles. This commitment must be reflected in the CSA agreement and implemented through actual cost-sharing payments.
2. Reasonably anticipate benefits from exploiting the cost-shared intangibles. Each participant must have a reasonable expectation of deriving economic benefits from the intangibles being developed through the IDA. This requirement ensures that cost-sharing participants are not merely passive funders but rather parties with a genuine commercial interest in the exploitation of the intangibles.
3. Exercise control over the IDA resources and capabilities that it provides. Each participant must exercise substantive control over the resources, capabilities, and rights that it contributes to the IDA. This requirement, which reflects the broader principle of economic substance, ensures that each participant has genuine involvement in the intangible development activity, rather than serving as a mere conduit for cost-sharing payments.
Substantive Involvement Requirement. The regulations contemplate that each controlled participant will have substantive involvement in the intangible development activity, commensurate with its role in the CSA. A participant that serves merely as a passive funder — contributing capital without exercising control or performing meaningful functions — may not satisfy the requirements for a controlled participant. The IRS has historically challenged CSA participants that lack operational substance, arguing that such entities are not bona fide controlled participants and that the CSA should be disregarded.
Application to PPC and PBI. PPC is the U.S.-based developer with substantial R&D operations, including approximately 4,200 research, clinical development, and regulatory affairs professionals and significant R&D facilities in New Jersey, Massachusetts, and California. PPC's role in the IDA consists primarily of conducting laboratory research, preclinical and clinical development, and U.S. regulatory activities. PPC is plainly a bona fide controlled participant under any reasonable interpretation of the regulations.
PBI's status as a bona fide controlled participant is the more likely subject of IRS challenge. The IRS may argue that PBI's primary role is that of a passive IP-holding company that contributes capital (in the form of cost-sharing payments) without performing substantive intangible development functions. However, the facts support PBI's eligibility as a controlled participant for the following reasons:
• Growing headcount and dedicated personnel. PBI employed 185 individuals as of 2020, with personnel dedicated to regulatory affairs, medical affairs, commercial strategy, market access, and supply chain functions. PBI's workforce grew from 52 employees at establishment to 185 employees by the end of the examination period, reflecting genuine operational expansion.
• Dublin-based regulatory and commercial-strategy personnel. PBI maintained a dedicated team of regulatory affairs professionals in Dublin who managed European Medicines Agency submissions, national regulatory filings in APAC markets, and post-marketing surveillance activities. PBI's regulatory team operated independently, with direct responsibility for obtaining and maintaining marketing authorizations in the non-Americas territories.
• Independent pricing decisions across 68 markets. PBI exercised independent authority over product pricing, market access negotiations, reimbursement strategies, and distribution partner selection across sixty-eight country markets. These decisions were made by PBI's Dublin-based management team under the oversight of PBI's board of directors, which held forty-two meetings in Dublin during the examination period.
• Significant capital expenditures on regulatory submissions. PBI incurred cumulative regulatory expenditures of approximately €47.2 million during the 2017–2020 period, reflecting its substantive involvement in the regulatory aspects of the IDA. These expenditures included costs related to marketing authorization applications, post-marketing studies, pharmacovigilance, and regulatory compliance.
• Market risk. PBI bore the economic risk of commercializing PPC's pharmaceutical products in the non-Americas territories, including the risk of adverse regulatory outcomes, competitive pressures, pricing and reimbursement constraints, and currency fluctuations.
Potential IRS Challenge and Rebuttal. The IRS may argue that PBI is a passive funder rather than a substantive participant in the IDA, focusing on the fact that the majority of laboratory R&D is conducted by PPC in the United States. However, the regulations do not require that each controlled participant perform identical functions; rather, each participant must exercise control over the resources and capabilities that it provides. PBI's contributions to the IDA include regulatory development activities, commercial strategy, and market development in the non-Americas territories — all of which are integral to the exploitation of the cost-shared intangibles. The regulatory framework recognizes that different participants may contribute different types of resources and capabilities, and the substantive involvement standard is satisfied when each participant exercises genuine control over its contributions and bears genuine economic risk. PBI's functional profile supports its status as a bona fide controlled participant.
C. Intangible Development Activity ("IDA")
Treasury Regulation § 1.482-7(j)(1)(i) defines the intangible development activity as any activity performed by controlled participants that is reasonably anticipated to contribute to developing, enhancing, maintaining, protecting, or exploiting cost-shared intangibles. The IDA is the central activity of the CSA, and the costs of the IDA are the costs that are shared among the controlled participants in proportion to their reasonably anticipated benefits.
Scope of the IDA. The IDA encompasses a broad range of activities that contribute to the development, enhancement, maintenance, protection, or exploitation of the intangibles covered by the CSA. In the pharmaceutical context, the IDA typically includes:
• Laboratory research — Discovery and preclinical development of new molecular entities, including target identification, lead optimization, and preclinical pharmacology and toxicology studies.
• Clinical development — Phase I, Phase II, and Phase III clinical trials, including study design, patient recruitment, data analysis, and clinical study reports.
• Regulatory activities — preparation and submission of regulatory filings (Investigational New Drug applications, New Drug Applications, marketing authorization applications), responses to regulatory queries, and post-marketing surveillance and pharmacovigilance.
• Market development — commercial strategy development, market access and reimbursement activities, key opinion leader engagement, and promotional activities.
• IP protection — patent prosecution, defense, and enforcement activities, as well as trade secret protection measures.
IDA in the PPC/PBI CSA. The CSA defines the IDA to include all R&D activities reasonably expected to benefit the covered IP portfolio, including laboratory research, clinical development, regulatory activities, and related supporting functions. R&D activities are conducted primarily at PPC's U.S. facilities (Princeton Junction, Cambridge, and San Diego), with PBI contributing regulatory and market-development activities for non-Americas territories. The IDA is broadly defined to capture the full spectrum of activities that contribute to the value of the cost-shared intangibles, consistent with the regulatory requirement that the IDA be clearly delineated in the CSA agreement.
The importance of clearly delineating the IDA in the CSA agreement cannot be overstated. A CSA that fails to adequately define the scope of the IDA risks challenge by the IRS on the grounds that the cost pool is either overinclusive (including costs that are not properly part of the IDA) or underinclusive (excluding costs that should be included). The PPC/PBI CSA defines the IDA with sufficient specificity to identify the covered activities and their relationship to the cost-shared intangibles, while retaining appropriate flexibility to accommodate the evolution of the R&D pipeline over time.
D. Cost Pool Composition
Treasury Regulation § 1.482-7(d) specifies the costs that must be included in the cost pool for purposes of calculating each controlled participant's share of IDA costs. Proper composition of the cost pool is essential to the integrity of the cost-sharing calculations and is frequently a focus of IRS examination.
Categories of Includable Costs. The cost pool must include all costs (direct and indirect) that are attributable to the IDA, including:
• Personnel costs (salaries, wages, benefits, and other compensation) for employees performing IDA-related functions;
• Materials and supplies consumed in IDA activities;
• Contract research and development costs, including payments to third-party contract research organizations;
• Depreciation and amortization of tangible and intangible assets used in the IDA;
• Allocable overhead costs, including rent, utilities, and administrative support reasonably allocable to IDA functions;
• Other costs directly or indirectly attributable to the IDA.
Stock-Based Compensation. The treatment of stock-based compensation ("SBC") in the CSA cost pool has been one of the most significant and contentious issues in cost-sharing jurisprudence. The Treasury regulations, as finalized in 2003, require the inclusion of SBC costs in the cost pool. However, the Ninth Circuit's decision in Altera Corp. v. Commissioner, 926 F.3d 1061 (9th Cir. 2019), which upheld the Tax Court's invalidation of the regulatory requirement to include SBC in the cost pool, created significant uncertainty. The Ninth Circuit's opinion was vacated following the death of Judge Reinhardt, whose vote was decisive, and a new panel was constituted. The reconstituted panel ultimately reversed the Tax Court and upheld the Treasury regulation requiring inclusion of SBC, but the Supreme Court denied certiorari, leaving the issue resolved for Ninth Circuit taxpayers while remaining uncertain in other circuits. PPC, as a New Jersey-headquartered company within the Third Circuit, faces a different appellate landscape. PPC's treatment of SBC in the CSA documentation, as prepared by Crestfield & Associates, includes SBC in the cost pool in accordance with the Treasury regulations, which we believe is the more defensible position under current law and consistent with the regulatory text.
PPC's Qualified R&D Cost Pools. PPC's qualified R&D cost pools for the examination years were as follows:
These cost pools were determined in accordance with the methodology set forth in the CSA agreement and documented contemporaneously in PPC's transfer pricing documentation prepared by Crestfield & Associates. The cost pools include direct and indirect R&D costs incurred by PPC in the United States, including personnel costs, contract research costs, materials, depreciation, and allocable overhead.
Treatment of PBI's Regulatory Submission Costs. PBI incurred cumulative regulatory expenditures of approximately €47.2 million during the 2017–2020 period. The treatment of these costs within the cost-sharing framework requires careful analysis. To the extent that PBI's regulatory submission costs constitute IDA costs (i.e., they are reasonably anticipated to contribute to the development, enhancement, maintenance, protection, or exploitation of the cost-shared intangibles), they should be included in the overall cost pool and allocated among the participants in proportion to their RAB shares. However, to the extent that certain of these costs represent activities specific to PBI's exploitation of the intangibles in the non-Americas territories (e.g., country-specific regulatory filings that benefit only the non-Americas markets), they may appropriately be treated as PBI's own exploitation costs and not included in the shared cost pool. The CSA agreement addresses this distinction, providing that regulatory costs incurred by PBI that are specific to the non-Americas markets are borne directly by PBI and are not included in the shared cost pool, while costs that benefit the global development of the cost-shared intangibles are included.
Consistency and Documentation. The methodology for determining the cost pool must be consistent with the terms of the CSA agreement and documented contemporaneously. Any changes in the methodology must be justified and documented. PPC's cost pool calculations have been prepared consistently for each examination year by Crestfield & Associates and are supported by detailed workpapers identifying the costs included in and excluded from the pool.
IV. Platform Contribution Transactions ("PCTs")
A. Regulatory Requirements for PCTs
Treasury Regulation § 1.482-7(g) provides that when a controlled participant makes a "platform contribution" — defined as a contribution of resources, capabilities, or rights that have been developed outside the intangible development activity and that are reasonably anticipated to contribute to the IDA — the other participants must make arm's-length payments to compensate for the value of the contribution. These payments are referred to as platform contribution transaction payments, or PCT payments.
A PCT arises most commonly at the inception of a CSA, when one party brings pre-existing intangible property into the arrangement. The rationale for the PCT requirement is straightforward: if one participant enters a CSA with valuable pre-existing intangibles (such as patented technology, trade secrets, clinical data, or regulatory approvals), the other participants receive a benefit from those contributions that exceeds their proportionate share of ongoing IDA costs. Without a PCT payment, the contributing participant would be subsidizing the other participants' access to valuable intangibles without arm's-length compensation.
Application to PPC and PBI. At the inception of the CSA on July 1, 2012, PPC contributed its pre-existing pharmaceutical intellectual property portfolio to the arrangement. This portfolio consisted primarily of clinical-stage and approved oncology compounds, associated know-how, manufacturing processes, clinical trial data, and regulatory filings. PBI, as the participant acquiring the right to develop and exploit this IP portfolio in the non-Americas territories, was required to make a PCT payment to PPC that reflected the arm's-length value of the platform contributions.
PBI made a lump-sum PCT payment of $312 million to PPC on July 1, 2012. This payment was determined through a discounted cash flow analysis prepared by Crestfield & Associates and was intended to represent the arm's-length value of PBI's anticipated benefits from PPC's pre-existing IP contributions, net of PBI's share of future IDA costs. The PCT payment was structured as a lump-sum cash payment rather than a series of contingent payments, consistent with the arm's-length standard and the parties' risk allocation.
B. PCT Valuation Methodologies Under § 1.482-7(g)(4)–(6)
The regulations specify several methods for determining the arm's-length value of PCT payments. These methods are subject to the best method rule of § 1.482-1(c), which requires the selection of the method that provides the most reliable measure of an arm's-length result under the facts and circumstances.
Income Method (§ 1.482-7(g)(4)). The income method determines the arm's-length PCT payment by reference to a discounted cash flow ("DCF") analysis of the anticipated income attributable to the platform contributions. Under this method, the PCT payment equals the present value of the anticipated incremental income that the recipient participant (PBI) is expected to derive from the platform contributions over their useful life, discounted at an appropriate risk-adjusted rate. The income method requires detailed projections of revenue, costs, and profitability for the relevant territories, as well as the selection of an appropriate discount rate that reflects the risk profile of the specific intangibles.
Acquisition Price Method (§ 1.482-7(g)(5)). The acquisition price method determines the arm's-length PCT payment by reference to the prices paid in comparable arm's-length acquisitions of similar intangible property. This method is analogous to the comparable uncontrolled transaction ("CUT") method and requires the identification of sufficiently comparable transactions. In practice, the acquisition price method is often difficult to apply because truly comparable transactions involving pharmaceutical IP are rare and typically involve different risk profiles, development stages, and therapeutic areas.
Market Capitalization Method (§ 1.482-7(g)(6)). The market capitalization method determines the arm's-length PCT payment through a residual profit split analysis based on the market capitalization of the controlled group. Under this method, the total value of the controlled group's intangibles is derived from the difference between the group's market capitalization and the value of its tangible assets and routine intangibles, and the PCT payment is determined as the recipient participant's share of this residual intangible value. The market capitalization method is often used as a reasonableness check rather than a primary valuation method, because market capitalization can be volatile and may reflect factors unrelated to the specific intangibles being contributed.
Unspecified Methods (§ 1.482-7(g)(7)). The regulations also permit the use of any other method that is consistent with the arm's-length standard and provides a reliable measure of an arm's-length result, provided that the method satisfies the best method rule.
Best Method Rule. The best method rule of § 1.482-1(c) requires that the selected method provide the most reliable measure of an arm's-length result under the facts and circumstances. Reliability is assessed based on the degree of comparability between the tested transaction and any comparable transactions, the quality of the data and assumptions used, and the sensitivity of the results to changes in key assumptions. In the context of PCT valuation, the income method is generally considered the most reliable method when detailed financial projections are available and an appropriate discount rate can be determined, because it most directly measures the value of the anticipated benefits from the platform contributions.
C. Application of Income Method to PPC's PCT
PPC, with the assistance of Crestfield & Associates and subsequently confirmed by the Whitmore Valuation Group LLC under Dr. Helena Vasquez's direction, applied the income method to determine the arm's-length PCT payment. The analysis employed a discounted cash flow model that projected PBI's anticipated income from exploiting PPC's pre-existing IP portfolio in the non-Americas territories, discounted at a risk-adjusted weighted average cost of capital.
Key Assumptions and Parameters. The income method analysis was based on the following key assumptions:
• Revenue projections: Product-level revenue projections for Veritaxol, Imvara, Cerulon, and other pipeline compounds were developed for the non-Americas territories based on market research, historical revenue trends, expected regulatory approvals, competitive dynamics, and anticipated pricing and reimbursement outcomes. These projections reflected the information available as of the CSA inception date (July 1, 2012) and were based on reasonable assumptions about market penetration, product lifecycle, and competitive entry.
• Cost assumptions: Operating costs, including cost of goods sold, selling and marketing expenses, regulatory costs, and general and administrative expenses, were projected based on PBI's anticipated operating model and benchmarked against comparable pharmaceutical companies.
• discount rate: PPC applied a weighted average cost of capital of 9.8%, which reflected the risk profile of PPC's pharmaceutical IP portfolio, including development risk (for clinical-stage compounds), regulatory risk, commercial risk, and the general uncertainty inherent in pharmaceutical revenue projections. The 9.8% WACC was derived from a capital asset pricing model analysis, incorporating PPC's equity beta, the risk-free rate prevailing as of July 2012, and an appropriate equity risk premium, with adjustments for the specific risk characteristics of the contributed IP portfolio.
• Useful life: The projected income stream was discounted over the anticipated useful life of the contributed intangibles, reflecting patent expiration dates, expected generic competition entry, and the anticipated duration of regulatory exclusivity in the non-Americas territories.
Resulting Arm's-Length Range. The DCF analysis produced an arm's-length range of $278 million to $361 million for the PCT payment. The $312 million PCT payment actually made by PBI falls within this range, at approximately the midpoint.
Anticipated IRS Challenge. The IRS, through its economist Dr. Alan Washburne, has independently valued the PCT at approximately $852 million. The IRS's valuation also applies the income method but uses significantly different assumptions:
• discount rate: The IRS applied a WACC of 7.2%, compared to PPC's 9.8%. The lower discount rate reflects the IRS's view that the risk profile of PPC's pharmaceutical IP portfolio was lower than PPC's analysis suggests. Dr. Washburne has indicated that the IRS applied a lower equity risk premium and a lower adjustment for specific IP risk.
• Revenue growth projections: The IRS applied higher revenue growth projections for PBI's non-Americas territories, reflecting a more optimistic view of market penetration, pricing, and regulatory approval timelines than PPC's contemporaneous projections.
The delta between the IRS's and PPC's valuations is $540 million ($852 million minus $312 million). This is a significant discrepancy and represents the single largest area of disagreement in the examination.
Critical Observation Regarding Examination Years. It is important to note that the PCT payment was made in 2012, which is outside the scope of the current examination (tax years 2017 through 2020). The IRS cannot directly adjust the 2012 PCT payment through this examination. Instead, the IRS seeks to use the alleged PCT undervaluation as a basis for increasing the ongoing cost-sharing ratios for the examination years, effectively asserting that the annual cost-sharing percentages should be higher to capture the residual value of the allegedly underpaid platform contributions. The legal basis for this approach is discussed in Section IV.D below.
Key Areas of Dispute on PCT Valuation. The defense of PPC's PCT valuation will focus on three principal areas:
1. discount rate. PPC's 9.8% WACC versus the IRS's 7.2% WACC is the most significant driver of the valuation difference. Dr. Vasquez of the Whitmore Valuation Group has prepared a detailed technical analysis supporting the higher discount rate, based on risk premiums derived from pharmaceutical industry cost of capital studies, beta comparables drawn from specialty pharmaceutical and biotechnology companies with similar development-stage portfolios, and adjustments for the specific risk characteristics of PPC's contributed IP (including clinical-stage compounds with uncertain regulatory outcomes). The analysis demonstrates that a 9.8% WACC is consistent with the risk profile of the specific intangibles contributed to the CSA, and that the IRS's 7.2% WACC understates the risk inherent in pharmaceutical IP valuations.
2. Revenue growth projections. The IRS's higher revenue projections reflect assumptions about non-Americas market penetration that were not supported by the information available as of the CSA inception date. The regulatory standard requires that projections be "reasonably anticipated" as of the date the CSA was entered into, not based on hindsight. PPC's contemporaneous projections, which were developed by Crestfield & Associates based on product-level market analysis available in 2012, represent a reasonable estimate of anticipated benefits at the time.
3. Useful life of contributed intangibles. Differences in the assumed useful life of the contributed intangibles affect the duration of the projected income stream and, consequently, the present value of the PCT. PPC's analysis reflects patent expiration dates and expected generic competition entry, while the IRS's analysis may assume a longer useful life based on different assumptions about brand loyalty, regulatory exclusivity, and lifecycle management strategies.
Regulatory Standard. The regulatory standard for the PCT payment is that it must compensate the contributing participant for the reasonably anticipated benefits from the platform contributions. The income method must use appropriate projections and discount rates that reflect the risk profile of the specific intangibles being contributed. The regulations do not require the use of the most aggressive assumptions or the lowest possible discount rate; rather, they require that the analysis be reasonable, consistent, and based on the information available at the time the CSA was entered into.
D. Interaction Between PCT and Ongoing Cost-Sharing
The relationship between the PCT payment and the ongoing cost-sharing payments is a critical issue in the IRS's examination strategy. Once the PCT payment has been made, the ongoing cost-sharing should reflect only the RAB from the intangible development activity — that is, the anticipated benefits from the intangibles being developed through the IDA, not the platform contributions for which the PCT payment has already been made. The PCT and the cost-sharing are independently determined; the PCT compensates for pre-existing contributions, while the cost-sharing allocates the costs of future development activities.
If the IRS asserts that the PCT was underpaid, it may seek to increase the ongoing cost-sharing percentages to capture the residual value of the allegedly underpaid platform contributions. This is precisely the approach the IRS has taken in the PPC examination: because the 2012 PCT payment year is outside the scope of the current examination, the IRS is seeking to adjust the 2017–2020 cost-sharing ratios upward to reflect what it characterizes as the higher value of PBI's anticipated benefits from the platform contributions.
Defensive Argument. This approach is subject to challenge on several grounds:
• Independent determination. The cost-sharing ratios and the PCT payment are independently determined under the regulations. The cost-sharing ratios reflect the participants' RAB shares from the IDA, not the value of the platform contributions. An alleged undervaluation of the PCT should not mechanically increase the cost-sharing percentages without a proper, independent analysis of RAB shares.
• Double-counting risk. If the IRS increases both the PCT value (for purposes of computing the residual benefit attributable to PBI) and the cost-sharing percentages, there is a risk of double-counting the value of the platform contributions. The regulations are designed to prevent double-counting by requiring separate determinations for the PCT and the cost-sharing.
• Correlative adjustments. Treasury Regulation § 1.482-1(g) provides that if adjustments are made to one component of intercompany pricing, correlative adjustments should be made to avoid double-counting. The IRS has recognized this principle by allowing a $42.65 million correlative offset in its proposed adjustments, but the adequacy of this offset is subject to dispute. If the IRS is using the alleged PCT undervaluation to increase the cost-sharing percentages, a full correlative adjustment may be required to avoid overstating PBI's total intercompany payments.
V. Reasonably Anticipated Benefits ("RAB")
A. Regulatory Standard
Treasury Regulation § 1.482-7(e) provides that each controlled participant's share of IDA costs must be proportional to its "reasonably anticipated benefits" from exploiting the cost-shared intangibles. The RAB standard is the cornerstone of the cost-sharing allocation: it ensures that each participant bears a share of the development costs that is commensurate with the share of benefits it expects to derive from the intangibles being developed.
RAB is generally measured by reference to anticipated future benefits from the intangibles being developed through the IDA. The most common measures of anticipated benefits are projected revenues, projected operating profits, units sold, or other economically meaningful measures of the benefits that each participant expects to derive. The chosen measure must be applied consistently over time, and the methodology for determining RAB shares must be specified in the CSA agreement and documented contemporaneously.
The critical feature of the RAB standard is that it is forward-looking. The measurement must be based on projections that are reasonable and consistently applied as of the date the costs are incurred. This forward-looking nature means that changes in RAB shares from year to year are permitted and expected as market conditions evolve, new information becomes available, and the relative anticipated benefits of the participants shift. However, the regulatory standard is "reasonably anticipated" benefits — not actual realized benefits. The use of hindsight to second-guess projections that were reasonable when made is not appropriate under the regulations.
B. RAB Measurement Methodology
The CSA between PPC and PBI uses projected revenue splits between Americas and non-Americas territories as the measure of RAB. This is a widely accepted and commonly used methodology in pharmaceutical cost-sharing arrangements, because revenue is a readily observable and economically meaningful measure of the benefits derived from pharmaceutical intangibles.
Revenue Projection Methodology. PBI's RAB shares were determined based on product-level revenue projections for Veritaxol, Imvara, Cerulon, and other covered products across the Americas and non-Americas territories. The projections were developed annually by PPC's financial planning and analysis team, in coordination with PBI's commercial strategy team, and were reviewed and documented by Crestfield & Associates as part of the annual transfer pricing documentation process.
The projections incorporated the following inputs:
• Historical revenue trends by product and territory;
• Anticipated regulatory milestones, including new marketing authorizations and label expansions;
• Competitive dynamics, including anticipated generic competition and biosimilar entry;
• Pricing and reimbursement assumptions by country or region;
• Market penetration assumptions based on epidemiological data and commercial intelligence;
• Currency assumptions based on forward exchange rates.
Non-Americas Revenue Share Growth. PBI's non-Americas revenue share grew over the 2017–2020 period as PBI expanded its commercial operations and achieved new regulatory approvals in additional markets. The resulting RAB shares and cost-sharing payments were:
The gradual increase in PBI's RAB share from 38.2% to 42.7% over the four-year period reflects genuine